Home >> Respiratory/Pulmonary >> Respiratory/Pulmonary >> Brands >> Technology & Media >>

Bronchiectasis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 74 | Code: MRS - 18308

Bronchiectasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bronchiectasis - Pipeline Review, H1 2015’, provides an overview of the Bronchiectasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchiectasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bronchiectasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bronchiectasis Overview 7
Therapeutics Development 8
Pipeline Products for Bronchiectasis - Overview 8
Pipeline Products for Bronchiectasis - Comparative Analysis 9
Bronchiectasis - Therapeutics under Development by Companies 10
Bronchiectasis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bronchiectasis - Products under Development by Companies 14
Bronchiectasis - Companies Involved in Therapeutics Development 15
Alitair Pharmaceuticals, Inc. 15
Bayer AG 16
Clarassance, Inc. 17
GlaxoSmithKline plc 18
Grifols, S.A. 19
Kamada Ltd. 20
Nostrum Pharmaceuticals, LLC 21
Pulmatrix, Inc. 22
Recipharm AB 23
Savara Inc. 24
Serendex Pharmaceuticals A/S 25
Bronchiectasis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
alpha-1 proteinase inhibitor (human) second generation - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ALT-07 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALT-09 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ARD-3150 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BAY-858501 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CG-1011 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ciprofloxacin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
dapsone - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
erdosteine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GSK-2793660 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Leukotriene B4 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
levofloxacin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
molgramostim - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Human Follistatin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
vancomycin hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Bronchiectasis - Recent Pipeline Updates 58
Bronchiectasis - Dormant Projects 64
Bronchiectasis - Discontinued Products 65
Bronchiectasis - Product Development Milestones 66
Featured News & Press Releases 66
Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia 66
Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation 66
Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm’s Pulmaquin for Non-Cystic Fibrosis Bronchiectasis 66
Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 67
Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 68
May 20, 2014: FDA Grants QIDP Designation to Aradigm’s Inhaled Antibiotic 69
May 05, 2014: Pulmatrix Presents Preclinical Data on iSPERSE Inhaled Antibiotics at the 2014 Respiratory Drug Delivery Conference 70
Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA 70
Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis 71
Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 71
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables
Number of Products under Development for Bronchiectasis, H1 2015 8
Number of Products under Development for Bronchiectasis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H1 2015 15
Bronchiectasis - Pipeline by Bayer AG, H1 2015 16
Bronchiectasis - Pipeline by Clarassance, Inc., H1 2015 17
Bronchiectasis - Pipeline by GlaxoSmithKline plc, H1 2015 18
Bronchiectasis - Pipeline by Grifols, S.A., H1 2015 19
Bronchiectasis - Pipeline by Kamada Ltd., H1 2015 20
Bronchiectasis - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2015 21
Bronchiectasis - Pipeline by Pulmatrix, Inc., H1 2015 22
Bronchiectasis - Pipeline by Recipharm AB, H1 2015 23
Bronchiectasis - Pipeline by Savara Inc., H1 2015 24
Bronchiectasis - Pipeline by Serendex Pharmaceuticals A/S, H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Bronchiectasis Therapeutics - Recent Pipeline Updates, H1 2015 58
Bronchiectasis - Dormant Projects, H1 2015 64
Bronchiectasis - Discontinued Products, H1 2015 65

List of Figures
Number of Products under Development for Bronchiectasis, H1 2015 8
Number of Products under Development for Bronchiectasis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Top 10 Targets, H1 2015 27
Number of Products by Stage and Top 10 Targets, H1 2015 28
Number of Products by Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30
Number of Products by Top 10 Routes of Administration, H1 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32
Number of Products by Top 10 Molecule Types, H1 2015 33
Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing